Stay updated on Camidanlumab Tesirine in Hodgkin Lymphoma Clinical Trial

Sign up to get notified when there's something new on the Camidanlumab Tesirine in Hodgkin Lymphoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Camidanlumab Tesirine in Hodgkin Lymphoma Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    No Change Detected
  4. Check
    3 days ago
    No Change Detected
  5. Check
    4 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a recent update in the number of participants enrolled in the study evaluating the efficacy and safety of Camidanlumab Tesirine (ADCT-301) in patients with relapsed or refractory Hodgkin Lymphoma.
    Difference
    0.1%
    Check dated 2024-06-06T14:49:27.000Z thumbnail image
  6. Check
    19 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to include detailed eligibility criteria for participants, specifying requirements such as informed consent, age, health conditions, and prior treatments. This change provides more comprehensive information for potential participants and researchers about who can join the study.
    Difference
    37%
    Check dated 2024-05-22T21:18:23.000Z thumbnail image
  7. Check
    41 days ago
    Change Detected
    Difference
    0.6%
    Check dated 2024-04-30T22:37:35.000Z thumbnail image

Stay in the know with updates to Camidanlumab Tesirine in Hodgkin Lymphoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Camidanlumab Tesirine in Hodgkin Lymphoma Clinical Trial page.